Regenerative medicine firm CollPlant launches Israel R&D center

The facilities will serve CollPlant for development of its products, including BioInks for 3D bioprinting of tissues and organs, and dermal fillers for medical aesthetics.

By REUTERS
May 23, 2019 19:18
1 minute read.
HEALTH & SCIENCE

HEALTH & SCIENCE. (photo credit: JPOST STAFF)

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

TEL AVIV - CollPlant, which makes products for tissue repair and organ manufacturing from its recombinant human collagen, has launched a new research and development center in Israel.

The facilities will serve CollPlant for development of its products, including BioInks for 3D bioprinting of tissues and organs, and dermal fillers for medical aesthetics, the company said on Wednesday.

Collagen is a protein found in tissues such as tendons, skin, blood vessels and bones. CollPlant produces collagen from tobacco plants genetically engineered with five human genes. Its first products approved for sale in Europe are used for tendonitis and wound care.

It will seek to commercialize these products in the United States, Chairman Jonathan Rigby said, adding: “We expect to secure more partnerships in the future.”


CollPlant is also working on dermal fillers to inject into wrinkles. While current fillers erode over time, the effects of human collagen last much longer, he told Reuters. The company expects approval for this product in 3 to 5 years.

In 2018, CollPlant signed an agreement with United Therapeutics Corp for the use of CollPlant’s BioInk for 3D bioprinting of lung scaffolds with a long-term goal of making transplantable lungs, subject to U.S. regulatory approval.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

A wild sunflower
June 26, 2019
The unseen battle against the wild sunflower

By ALON EINHORN

Cookie Settings